Related Experiment Video
Updated: Mar 18, 2026

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library
Published on: April 6, 2012
MicroRNA-216b is downregulated in hepatocellular carcinoma and inhibits HepG2 cell growth by targeting Forkhead box
1Department of Gastroenterology, Weifang Traditional Chinese Hospital, Weifang City, Shandong Province, China. zww554478@163.com.
Objective:
Aberrantly expressed microRNAs (miRs) may play critical roles in the regulation of tumorigenicity of various cancers. The present study was designed to investigate the expression, function and the underlying mechanism of miR-216b in hepatocellular carcinoma (HCC).
Materials And Methods:
The expression of miR-216b and FOXM1 in 24 paired HCC tissues and adjacent normal tissues was determined by Real-time PCR. The proliferative activity of HepG2 cells was determined by MTT assay. We analyzed cell cycle progression by flow cytometry, apoptosis by cell death enzyme-linked immunosorbent assay (ELISA) and cleaved-caspase-3 by western blot. Luciferase reporter assay was employed to verify whether FOXM1 serves as a target of miR-216b in vitro.
Results:
The expression of miR-216b was significantly decreased in HCC tissues compared with that in adjacent normal tissues, whereas FOXM1 expression was increased. In addition, FOXM1 and miR-216b expression were inversely correlated in HCC tissues. Ectopic expression of miR-216b produced a suppressive effect on the growth of HepG2 cells and induced cell cycle arrest and apoptosis. We further demonstrated that miR-216b targets the 3' untranslated region (UTR) of FOXM1 directly to suppress the expression of FOXM1, and that suppression of FOXM1 produced the similar effects to miR-216b
Conclusions:
These data suggest that down-regulation of miR-216b directly contributes to the up-regulation of FOXM1, which may confer the tumorigenicity of HCC cells. MiR-216b may serve as a potential therapeutic agent for HCC.
Insights
Decreased microRNA-216b (miR-216b) expression in hepatocellular carcinoma (HCC) promotes tumor growth by upregulating FOXM1. Restoring miR-216b levels may offer a potential therapeutic strategy for HCC.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Aberrant microRNA (miRNA) expression is implicated in cancer development.
- MicroRNAs play crucial roles in regulating cellular processes, including tumorigenesis.
- Hepatocellular carcinoma (HCC) is a significant global health concern with complex molecular underpinnings.
Purpose of the Study:
- To investigate the expression profile of miR-216b in hepatocellular carcinoma (HCC).
- To elucidate the functional role of miR-216b in HCC cell proliferation, cell cycle, and apoptosis.
- To identify the molecular mechanism underlying miR-216b's function, specifically its interaction with FOXM1.
Main Methods:
- Quantitative Real-time PCR (qRT-PCR) to assess miR-216b and FOXM1 expression in HCC tissues.
- In vitro assays including MTT for proliferation, flow cytometry for cell cycle analysis, and ELISA for apoptosis.
- Western blot analysis for cleaved-caspase-3 and luciferase reporter assays to validate direct targeting of FOXM1 by miR-216b.
Main Results:
- miR-216b was significantly downregulated, while FOXM1 was upregulated in HCC tissues, showing an inverse correlation.
- Overexpression of miR-216b suppressed HepG2 cell proliferation, induced cell cycle arrest, and promoted apoptosis.
- miR-216b was confirmed to directly target the 3' UTR of FOXM1, leading to decreased FOXM1 expression.
Conclusions:
- Downregulation of miR-216b contributes to hepatocellular carcinoma (HCC) tumorigenicity by increasing FOXM1 levels.
- The miR-216b/FOXM1 axis represents a critical regulatory pathway in HCC.
- miR-216b holds potential as a therapeutic target or agent for HCC treatment.
Related Concept Videos
MicroRNAs
MicroRNAs
MicroRNAs
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation

